Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations
Prenatal Diagnosis · 2026-11-21
DOI: 10.1002/pd.70314 ↗At a glance
Journal article in Prenatal Diagnosis, published online on 2026-11-21. Written by Alexandros Abdel Massih and 15 co-authors. 110 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fetal Medicine Foundation, Carlsbergfondet, Medical Research Centre.
Abstract (original language)
Sickle cell disease (SCD) is a monogenic hemoglobinopathy with inequities in morbidity and care within and between countries. Prenatal somatic gene therapy is proposed but remains preclinical for SCD. This critical narrative review examines how such an intervention would interact with existing disparities and evaluates it in terms of autonomy, beneficence, non‐maleficence, and justice. SCD differs from conditions for which fetal intervention is established: fetal hemoglobin is protective, clinical manifestations generally arise after its postnatal decline, and newborn screening permits early preventive care. A prenatal intervention must therefore demonstrate a material advantage over timely postnatal management while exposing neither the pregnant person nor fetus to disproportionate procedural or product risk. Intended somatic treatment is not equivalent to heritable genome editing or embryo selection, although off‐target effects, mosaicism and unintended germline exposure require explicit investigation. There is currently no evidence that prenatal somatic gene therapy is cost‐effective or would overcome access barriers. Its reliance on fetal medicine, molecular, and manufacturing infrastructure could initially widen disparities. Clinical translation would be ethically defensible only after disease‐specific comparative evidence, independent oversight, non‐directive consent, lifelong follow‐up and a credible equitable‐access plan. Strengthening newborn screening and proven care remains the immediate justice priority.
Funding
- Fetal Medicine Foundation
- Carlsbergfondet
- Medical Research Centre
Cite
APA
Massih, A. A., Riolini, A., Rai, S., Ammar, Z., Kaiser, L., Bell‐Ricketts, M. J., Sallie, L., Oteng‐Ntim, E., Vlachodimitropoulou, E., Nicolaides, K. H., Miccio, A., Chiappini, C., Strouboulis, J., Hoss, S. E., Monreal, M. T. M., & Shangaris, P. (2026). Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations. Prenatal Diagnosis. https://doi.org/10.1002/pd.70314
Vancouver
Massih AA, Riolini A, Rai S, Ammar Z, Kaiser L, Bell‐Ricketts MJ, et al. Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations. Prenatal Diagnosis. 2026. doi:10.1002/pd.70314
BibTeX
@article{Massih2026,
author = {Massih, Alexandros Abdel and Riolini, Aurora and Rai, Saffron and Ammar, Zuzanna and Kaiser, Lisa and Bell‐Ricketts, Morgan Jean and Sallie, Leila and Oteng‐Ntim, Eugene and Vlachodimitropoulou, Evangelia and Nicolaides, Kypros H. and Miccio, Annarita and Chiappini, Ciro and Strouboulis, John and Hoss, Sara El and Monreal, María Teresa Martín and Shangaris, Panicos},
title = {Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70314}
}
EUVIMED